Evidence map›Paper›PMID 35210895›Full record

ArticleJournal of blood medicine2022

Circulating miR-126-3p and miR-423-5p Expression in de novo Adult Acute Myeloid Leukemia: Correlations with Response to Induction Therapy and the 2-Year Overall Survival.

Faez Almohsen, Haithem A Al-Rubaie, Manal A Habib, Sherif A Nasr, Rajendra Perni, Lubab Al-Quraishi

Open access · goldAbstract read
In one paragraph

Article in Journal of blood medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Faez AlmohsenCollege of Medicine, University of Baghdad, Baghdad, Iraq.
Haithem A Al-RubaieCollege of Medicine, University of Baghdad, Baghdad, Iraq.ORCID 0000-0002-5818-125X
Manal A HabibCollege of Medicine, University of Baghdad, Baghdad, Iraq.
Sherif A NasrsiParadigm Diagnostic Informatics, New Jersey, NJ, USA.
Rajendra PernisiParadigm Diagnostic Informatics, New Jersey, NJ, USA.
Lubab Al-QuraishisiParadigm Diagnostic Informatics, New Jersey, NJ, USA.
University of Baghdad · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute myeloid leukemia (AML) results from sequential genetic alterations in a normal hematopoietic stem cell or its progenitors giving rise to an autonomous clone that dominates the bone marrow leading to marrow failure. MicroRNAs are short non-coding nucleic acid sequences that regulate post-transcriptional gene expression by base-pairing with their target mRNAs. MiRNAs can be secreted into extracellular fluids and carried to target cells by vesicles or bound to proteins. Intracellular and circulating miRNAs are believed to be useful markers in the diagnosis, prognosis, and treatment of various cancers. Practically, circulating miRNAs are more stable at room temperatures and extreme conditions. PURPOSE: This study aimed to compare the expression of miR-126-3p and miR-423-5p in patients and normal subjects and correlate their expression with response to induction therapy and with their 2-year overall survival rate. PATIENTS AND

methodsCirculating miR-126-3p and miR-423-5p was measured in the plasma of 43 adult AML patients and 35 age- and sex-matched controls by quantitative reverse transcriptase PCR. The fold change in differential expression for each gene was calculated using the comparative cycle threshold method.

resultsThere was an increase in the expression of the studied miRNAs in patients compared to the control group. The average expression fold change of miR-126-3p was 3.02 (

conclusionAlthough further studies are needed, our findings highlight the studied circulating miRNAs as possible diagnostic markers for AML.

Indexed as

acute myeloid leukemiamiR-126-3pmiR-423-5poverall survivalpolymerase chain reactionresponse to induction therapy

Identifiers

PMID35210895
PMCPMC8863343
OpenAlexW4212890073

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.